The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
复制标题
DOI：
10.4081/oncol.2017.324
复制
发表时间：
2017-01-01
期刊：
影响因子：
3.6
通讯作者：
Raez, Luis Estuardo
中科院分区：
文献类型：
--
作者：
Castrellon, Aurelio Bartolome;Pidhorecky, Ihor;Raez, Luis Estuardo
三阴性乳腺癌（TNBC）是一组具有组织学和分子差异的异质性疾病。TNBC患者对新辅助化疗（NACT）的完全病理学反应与改善的结局相关。已经努力确定药物组合，将增加反应率术前化疗。在这篇综述中，我们介绍了最近的研究，已纳入卡铂（Cb）在NACT的TNBC。我们讨论了同源重组缺陷评分和BRCA的体细胞或生殖系突变作为未来选择患者的潜在生物标志物，这些患者可能受益于NACT中添加Cb。
Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT.